Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INSULET CORPPODD · Entity 3516 | Director · President and CEO | August 21, 2026 | August 24, 2026 |
| JOHNSON & JOHNSONJNJ · Entity 2722 | EVP, WW Chair, MedTech | August 23, 2023 | August 25, 2023 |
| PROCTER & GAMBLE CoPG · Entity 2814 | Director | October 13, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INSULET CORP
Report date August 21, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,731 |
Reported balance
After 2026-08-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-21 · Purchase · Acquired 1,100 · Balance 23,731 F1: The price reported represents the weighted average purchase price of the shares acquired. The shares were purchased in multiple transactions at prices ranging from $147.42 to $147.62. The Reporting Person hereby undertakes, upon the request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price. F2: Includes 80 shares acquired under the Insulet Corporation Employee Stock Purchase Plan since the date of the Reporting Person's last Form 4 filing. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 4 |
Reported balance
Holding disclosure · report date 2026-08-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported represents the weighted average purchase price of the shares acquired. The shares were purchased in multiple transactions at prices ranging from $147.42 to $147.62. The Reporting Person hereby undertakes, upon the request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
F2: Includes 80 shares acquired under the Insulet Corporation Employee Stock Purchase Plan since the date of the Reporting Person's last Form 4 filing.
JOHNSON & JOHNSON
Report date August 23, 2023 · Filed August 25, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,037.9545 |
Reported balance
After 2023-08-23 transaction · row 1
1 source rowRow 1 · 2023-08-23 · Disposition to issuer · Disposed 2,787 · Balance 52,037.9545 F1: The Compensation & Benefits Committee of the Board of Directors of Johnson & Johnson approved the disposition of these shares of Johnson & Johnson common stock. F2: On August 23, 2023, Johnson & Johnson commenced a registered exchange offer to holders of shares of Johnson & Johnson common stock to exchange Johnson & Johnson common stock for Kenvue Inc. (Kenvue) common stock. The final exchange ratio was 8.0324 shares of Kenvue common stock per share of Johnson & Johnson common stock accepted in the exchange offer. |
| Common StockSEC Table I · non-derivative | IndirectBy 401k | 2,806 |
Reported balance
Holding disclosure · report date 2023-08-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,806 F3: Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (7/31/2023). |
| Common StockSEC Table I · non-derivative | IndirectBy ESOP | 300 |
Reported balance
Holding disclosure · report date 2023-08-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 300 F4: Shares held by ESOP under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (7/31/2023). |
Filing footnotes · ownership attribution and instrument terms
F1: The Compensation & Benefits Committee of the Board of Directors of Johnson & Johnson approved the disposition of these shares of Johnson & Johnson common stock.
F2: On August 23, 2023, Johnson & Johnson commenced a registered exchange offer to holders of shares of Johnson & Johnson common stock to exchange Johnson & Johnson common stock for Kenvue Inc. (Kenvue) common stock. The final exchange ratio was 8.0324 shares of Kenvue common stock per share of Johnson & Johnson common stock accepted in the exchange offer.
F3: Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (7/31/2023).
F4: Shares held by ESOP under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (7/31/2023).
PROCTER & GAMBLE Co
Report date October 13, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,666.0049 |
Reported balance
After 2026-10-13 transaction · row 1
1 source rowRow 1 · 2026-10-13 · Grant · Acquired 1,438 · Balance 7,666.0049 F1: Common Stock awarded pursuant to The Procter & Gamble 2025 Stock and Incentive Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Common Stock awarded pursuant to The Procter & Gamble 2025 Stock and Incentive Compensation Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2021 Filed Feb 10, 2021 23:47 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantEmployee Stock Options (Right to Buy) · Derivative | 68,894 | $0.00 Strike: $164.62 | $0.00 |
DisclosureSEC source: 0001225208-21-002097 · doc4.xml · derivative · entry 1 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,894 Underlying: Common Stock · 68,894 shares Expires 2031-02-08 F1 · security: Awarded under Issuer's Long-Term Incentive Plan. Read SEC document |
| July 28, 2020 Filed Jul 28, 2020 22:43 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | SaleCommon Stock | 29,000 | $147.47 | $4,276,630.00 |
DisclosureSEC source: 0001225208-20-010009 · doc4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,681.5018 F1 · price: This transaction was executed in multiple trades at prices ranging from $147.33 to $147.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 22:03 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 6,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002662 · doc4.xml · derivative · entry 8 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,602 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 13, 2017; converted into shares of Common Stock upon vesting. F2 · derivative.expiration_date: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 13, 2017; converted into shares of Common Stock upon vesting. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 22:03 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionPerformance Share Units · Derivative | 7,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002662 · doc4.xml · derivative · entry 7 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,145 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 13, 2017; converted into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 13, 2017; converted into shares of Common Stock upon vesting. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 22:03 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 3,031 | $150.46 | $456,044.26 |
DisclosureSEC source: 0001225208-20-002662 · doc4.xml · nonDerivative · entry 4 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,664.1929 F4 · shares: Shares withheld for payment of taxes upon vesting of Performance Share Units. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 22:03 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 2,801 | $150.46 | $421,438.46 |
DisclosureSEC source: 0001225208-20-002662 · doc4.xml · nonDerivative · entry 3 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,695.1929 F3 · shares: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 22:03 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 6,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002662 · doc4.xml · nonDerivative · entry 2 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,496.1929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 13, 2017; converted into shares of Common Stock upon vesting. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 22:03 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 7,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002662 · doc4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,894.1929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 13, 2017; converted into shares of Common Stock upon vesting. Read SEC document |
| February 10, 2020 Filed Feb 13, 2020 00:31 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantRestricted Share Units · Derivative | 2,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002109 · doc4.xml · derivative · entry 3 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,999 Underlying: Common Stock · 2,999 shares Expires not disclosed F4 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant. F4 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant. Read SEC document |
| February 10, 2020 Filed Feb 13, 2020 00:31 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantPerformance Share Units · Derivative | 7,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002109 · doc4.xml · derivative · entry 2 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,145 Underlying: Common Stock · 7,145 shares Expires not disclosed F2 · derivative.exercise_price: On February 10, 2020, the Issuer's Compensation & Benefits Committee certified the performance factor applicable to Performance Share Units awarded to the reporting person on February 13, 2017 under the Issuer's Long-Term Incentive Plan. These Performance Share Units represent a contingent right to an equal number of shares of Common Stock or the cash value thereof, subject to the reporting person's continued service to the Issuer through the third anniversary of the initial award date F3 · derivative.expiration_date: On February 10, 2020, the Issuer's Compensation & Benefits Committee certified the performance factor applicable to Performance Share Units awarded to the reporting person on February 13, 2017 under the Issuer's Long-Term Incentive Plan. These Performance Share Units represent a contingent right to an equal number of shares of Common Stock or the cash value thereof, subject to the reporting person's continued service to the Issuer through the third anniversary of the initial award date Read SEC document |
| February 10, 2020 Filed Feb 13, 2020 00:31 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantEmployee Stock Options (Right to Buy) · Derivative | 76,712 | $0.00 Strike: $151.41 | $0.00 |
DisclosureSEC source: 0001225208-20-002109 · doc4.xml · derivative · entry 1 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,712 Underlying: Common Stock · 76,712 shares Expires 2030-02-10 F1 · security: Awarded under Issuer's Long-Term Incentive Plan. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 00:31 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 38,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-001597 · doc4.xml · derivative · entry 5 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 1, 2017; converted into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 1, 2017; converted into shares of Common Stock upon vesting. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 00:31 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 15,405 | $149.32 | $2,300,274.60 |
DisclosureSEC source: 0001225208-20-001597 · doc4.xml · nonDerivative · entry 2 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,748.5197 Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 00:31 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 38,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-001597 · doc4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,153.5197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 1, 2017; converted into shares of Common Stock upon vesting. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 02:14 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantRestricted Share Units · Derivative | 2,885 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002349 · doc4.xml · derivative · entry 11 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,885 Underlying: Common Stock · 2,885 shares Expires not disclosed F10 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant. F10 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 02:14 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionPerformance Share Units · Derivative | 7,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002349 · doc4.xml · derivative · entry 10 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,541 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 8, 2016; converted into shares of Common Stock upon vesting of Performance Share Units and certification of performance results by the Board. F3 · derivative.expiration_date: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 8, 2016; converted into shares of Common Stock upon vesting of Performance Share Units and certification of performance results by the Board. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 02:14 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantEmployee Stock Options (Right to Buy) · Derivative | 58,972 | $0.00 Strike: $131.94 | $0.00 |
DisclosureSEC source: 0001225208-19-002349 · doc4.xml · derivative · entry 9 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,972 Underlying: Common Stock · 58,972 shares Expires 2029-02-11 F9 · security: Awarded under Issuer's Long-Term Incentive Plan. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 02:14 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 3,578 | $131.94 | $472,081.32 |
DisclosureSEC source: 0001225208-19-002349 · doc4.xml · nonDerivative · entry 5 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,468.4243 F5 · shares: Shares withheld for payment of taxes upon vesting of Performance Share Units and certification of performance results by the Board. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 02:14 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantCommon Stock | 1,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002349 · doc4.xml · nonDerivative · entry 4 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,046.4243 F4 · shares: Shares earned due to performance factor of 116.4% upon vesting of Performance Share Units and certification of performance results by the Board. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 02:14 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 7,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002349 · doc4.xml · nonDerivative · entry 3 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,809.4243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 8, 2016; converted into shares of Common Stock upon vesting of Performance Share Units and certification of performance results by the Board. Read SEC document |
| February 08, 2019 Filed Feb 13, 2019 02:14 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 6,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002349 · doc4.xml · derivative · entry 8 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each Restricted Share Unit, awarded under Issuer's Long-Term Incentive Plan on February 8, 2016, represents a contingent right to receive one share of Common Stock, and vests on the third anniversary of the grant date. F8 · derivative.expiration_date: Each Restricted Share Unit, awarded under Issuer's Long-Term Incentive Plan on February 8, 2016, represents a contingent right to receive one share of Common Stock, and vests on the third anniversary of the grant date. Read SEC document |
| February 08, 2019 Filed Feb 13, 2019 02:14 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 1,824 | $132.00 | $240,768.00 |
DisclosureSEC source: 0001225208-19-002349 · doc4.xml · nonDerivative · entry 2 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,268.4243 F2 · shares: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| February 08, 2019 Filed Feb 13, 2019 02:14 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 6,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002349 · doc4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,092.4243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 8, 2016; converted into shares of Common Stock upon vesting. Read SEC document |
| August 27, 2018 Filed Sep 17, 2018 21:51 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherCommon Stock | 142 | $134.92 | $19,158.64 |
DisclosureSEC source: 0001225208-18-013499 · doc4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Indirect · By 401k Disclosed balance after: 2,215 F1 · balance_after: Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.